These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37651827)

  • 21. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
    Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-enhanced CT-based radiomic analysis for determining the response to anti-programmed death-1 therapy in esophageal squamous cell carcinoma patients: A pilot study.
    Yang Q; Huang H; Zhang G; Weng N; Ou Z; Sun M; Luo H; Zhou X; Gao Y; Wu X
    Thorac Cancer; 2023 Nov; 14(33):3266-3274. PubMed ID: 37743537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian T; Liu D; Cao G; Chen Z; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidetector CT for Restaging Locally Advanced Esophageal Squamous Cell Carcinoma and Assessing Therapeutic Response to Neoadjuvant Chemotherapy.
    Shi Y; Chen Y; Li X; Wang Z; Sun Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Feb; 39(1):133-139. PubMed ID: 28270296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma.
    Wang JL; Tang LS; Zhong X; Wang Y; Feng YJ; Zhang Y; Liu JY
    Front Immunol; 2024; 15():1405146. PubMed ID: 38947338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and without immunotherapy: a retrospective cohort study.
    Liu L; Liu Y; Xu L; Ding Y; Han J; Wang Q; Chen X; Almhanna K; Han C; Wang L
    J Thorac Dis; 2024 Jun; 16(6):3909-3922. PubMed ID: 38983179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus.
    Dewan A; Sharma SK; Dewan AK; Khurana R; Gupta M; Pahuja A; Srivastava H; Sinha R
    J Gastrointest Cancer; 2017 Mar; 48(1):42-49. PubMed ID: 27604122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel quantitative model based on gross tumor volume corresponding to anatomical distribution measured with multidetector computed tomography to determine the resectability of non‑distant metastatic esophageal squamous cell carcinoma.
    Gao D; Ou J; Tan BG; Yu ZY; Li KY; Li R; Zhang XM; Chen TW; Zhou HY
    Oncol Lett; 2023 Nov; 26(5):485. PubMed ID: 37818136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival.
    Wang P; Lei M; Weng G; Huang R; Lin H; Wei W; Chen Y; He H; Chen P; Zhang D; Chen W; Zhou H; Gao P; Liu S; Wang F
    Transl Oncol; 2023 Oct; 36():101736. PubMed ID: 37478670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can Lymphovascular Invasion be Predicted by Preoperative Contrast-Enhanced CT in Esophageal Squamous Cell Carcinoma?
    Chen W; Wang Y; Bai G; Hu C
    Technol Cancer Res Treat; 2022; 21():15330338221111229. PubMed ID: 35790460
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative parameters derived from dual-energy computed tomography for the preoperative prediction of early recurrence in patients with esophageal squamous cell carcinoma.
    Liu Y; Cheng F; Wang L; Du L; Shen H; Wang X; Zeng Z; Liu D; Tao J; Wu J; Zhang J
    Eur Radiol; 2023 Nov; 33(11):7419-7428. PubMed ID: 37314470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer.
    Han W; Weng K; Zhang P; Hong Z
    Front Surg; 2022; 9():1091601. PubMed ID: 36684142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma.
    Hu Y; Xie C; Yang H; Ho JWK; Wen J; Han L; Lam KO; Wong IYH; Law SYK; Chiu KWH; Vardhanabhuti V; Fu J
    Radiother Oncol; 2021 Jan; 154():6-13. PubMed ID: 32941954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy.
    Yan S; Li FP; Jian L; Zhu HT; Zhao B; Li XT; Shi YJ; Sun YS
    BMC Cancer; 2023 May; 23(1):477. PubMed ID: 37231388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
    Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
    [No Abstract]   [Full Text] [Related]  

  • 39. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.